
Blinatumomab (Blincyto) gained accelerated approval by the FDA for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Blinatumomab (Blincyto) gained accelerated approval by the FDA for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Researchers analyzed Bing.com search logs to identify those recently diagnosed with pancreatic cancer. Through symptom patterns expressed as searches, they were able to identify 5% to 15% of pancreatic cancer cases.
Following on a 10-month improvement in progression-free survival (PFS), the FDA has approved ofatumumab (Arzerra) in combination with fludarabine and cyclophosphamide as a treatment for patients with with relapsed chronic lymphocytic leukemia (CLL).
MammaPrint has been shown to improve prediction of clinical outcomes in women with early-stage breast cancer.
At 23, Lindsay Kahn when she was diagnosed with stage 2 refractory Hodgkin lymphoma. Kahn describes the site IHadCancer.com as a “safe haven,” and says it’s a staple of her daily experience.
Patients undergoing Androgen-deprivation therapy (ADT) for prostate cancer may be at risk of significant psychological effects.
Colorectal cancer mortality rates have been on the decline in California for both men and women since the mid-1990s, but for one group—Hispanic men—rates have remained essentially unchanged, and a new study suggests that lower rates of screening may be the chief driver of this disparity.
COA created the CAPP network to enable APPs to review important practice issues and discuss solutions among themselves.
A large, population-based study found that obesity more prevalent in patients with a history of cancer than in the general population, suggesting an important area of focus and a need for improved weight management and control programs targeted at survivors’ specific needs.
METAvivor is dedicated to the specific fight of women and men living with stage 4 metastatic breast cancer.
Some immune-related adverse events (irAEs) can be life threatening. Researchers in Spain recently published a review of the most common endocrine irAEs and their management strategies.
A recent study explored the link between the genetic mutations and cisplatin-induced hearing loss.
While meeting with your doctor, or after meeting with them, you should keep the definitions of proactive and reactive in mind.
Studies find the addition of rolapitant to the CINV regimen gave a clinically meaningful benefit with no added toxicity.
A study has found that telephone cancer genetic counseling can be just as effective as in-person counseling for women at risk for hereditary breast and ovarian cancer
CURE asked Rebecca Nellis common questions about returning to work during or after cancer treatment.
Stress may have a negative impact on your health but you’re never going to be completely rid of stress. The key isn’t in doing away with all of life’s pressures, but in how you handle them on a daily basis.
New practice guideline now recommends a 2-mm margin width as the standard for patients with DCIS undergoing breast-conserving surgery.
ASCO guidelines on pain management for adult cancer survivors are first of their kind specifically directed to cancer survivors.
Breast cancer is the leading cause of cancer deaths among Black women of all ages and is increasing in younger women in the U.S.
While urinary incontinence and erectile dysfunction are two burdensome side effects from prostate cancer treatment, new online programs are showing promise in helping men cope in both the short and long term.
The National Leiomyosarcoma Foundation believes that a knowledgeable patient is a powerful patient, a patient that is able to be a strong self-advocate.